Global Registry and Natural History Study for Mitochondrial Diseases
Tracking Disease Progression and Supporting Clinical Trials Worldwide
Led by LMU Klinikum · Updated on 2026-08-07
6000
Participants Needed
34
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to create a global registry for mitochondrial disorders to unify previous national registries, allowing worldwide participation and supporting studies on the natural history of these diseases. The project is part of the EU-funded GENOMIT initiative, coordinated by Dr. Holger Prokisch at Technische Universitt Mnchen, and intends to improve the design and execution of clinical trials while promoting the translation of basic research into clinical practice.
The study collects data from existing networks such as mitoNET in GermanyAustria and Mitocon in Italy, with the possibility of including other countries. Participants with suspected or confirmed mitochondrial diseases are followed with annual assessments using standardized scales like the Newcastle Mitochondrial Disease Scale for Adults and Children, the Scale for the Assessment and Rating of Ataxia, and measures of disease progression.
Participants are monitored over a long period, up to 30 years or until discontinuation or death. Annual evaluations assess disease status and progression. The registry complies with national ethics and data protection rules, managing data access accordingly. This setup aims to support natural history studies and facilitate future clinical trials for mitochondrial disorders worldwide.
CONDITIONS
Brief Title
Global Registry and Natural History Study for Mitochondrial Disorders
Research Team
B
Boriana Büchner, Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Participants are screened for eligibility to participate in the trial.
Monitoring
Duration - Up to 30 years
Participants undergo annual assessments to track disease progression using standardized scales. Follow-up continues for up to 30 years or until discontinuation or death.
Annual visits
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Long-Term Follow-Up Study Monitoring Participants Previously Treated with TScan TCR-T Cell Therapies for AML, ALL, or MDS
Phase 1 Study of CG009301 Injection for Adults with Relapsed or Refractory Blood Cancers
Evaluating Safety, Dosage, and Effectiveness in Leukemia and Related Disorders
Phase 1 Study of Oral Tetrahydrouridine and Decitabine for Treating Relapsed or Refractory Myelodysplastic Syndromes
Evaluating Allogeneic Hematopoietic Stem Cell Transplantation
for Patients with GATA2 Mutations or MonoMAC Syndrome
Using Different Donor Types and Conditioning Regimens
Studying Passive and Active Exercise Effects Using pGz and Cardiopulmonary Testing
in Patients with Primary Mitochondrial Disease and Healthy Volunteers
Monitoring Measurable Residual Disease Using Digital PCR to Predict Relapse After Stem Cell Transplant in Leukemia and Related Blood Disorders
Phase II Study of Intensity Modulated Total Marrow Irradiation Added to Chemotherapy for Haploidentical Stem Cell Transplant in Adults with Acute Leukemia or Myelodysplastic Syndrome
Phase 1 Study of CD70-CAR T-cell Therapy with Chemotherapy for Children and Young Adults Up to 21 Years With Relapsed or Refractory Blood Cancers
Randomized, Double-Blind Trial Evaluating Daily Elamipretide Injections
for Male Patients With Genetically Confirmed Barth Syndrome
Assessing Efficacy and Safety Over 72 Weeks
Using RNA Sequencing from Blood and Skin Samples to Improve Diagnosis of Mitochondrial Diseases
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy.
Michelangelo Mancuso, Robert McFarland, Thomas Klopstock...